首页> 外文期刊>Neuropharmacology >Noradrenergic antidepressant responses to desipramine in vivo are reciprocally regulated by arrestin3 and spinophilin
【24h】

Noradrenergic antidepressant responses to desipramine in vivo are reciprocally regulated by arrestin3 and spinophilin

机译:体内去甲肾上腺素的去甲肾上腺素能抗抑郁药的反应由restarin3和spinophilin相互调节

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Many antidepressant drugs, including the tricyclic antidepressant desipramine (DMI), are broadly understood to function by modulating central noradrenergic neurotransmission. α 2 adrenergic receptors (α 2ARs) are key regulators of the noradrenergic system, and previous work has implicated α 2ARs in mediating the antidepressant activity of DMI in the rodent forced swim test (FST). However, little is known about intracellular regulators of antidepressant drug action. α 2AR function is tightly regulated by its intracellular interacting partners arrestin and the dendritic protein spinophilin. We have previously established the competitive and reciprocal nature of these interacting proteins at the α 2AR in the context of classic agonist effects, and have shown DMI to be a direct arrestin-biased ligand at the receptor. In the present study, we report that mice deficient in the α 2AAR subtype lack DMI-induced antidepressant behavioral effects in the FST. As well, mice deficient in arrestin3 lack antidepressant response to DMI, while spinophilin-null mice have enhanced antidepressant response to DMI compared with wild-type controls, indicating that this α 2AAR-mediated response is reciprocally regulated by arrestin and spinophilin. The characteristic of α 2AAR-dependence and arrestin3 involvement was shared by the antidepressant effect of the classic α 2AR agonist clonidine but not the non-tricyclic norepinephrine reuptake inhibitor reboxetine, supporting a model whereby DMI exerts its antidepressant effect through direct engagement of the α 2AAR and arrestin3. Our results implicate arrestin- and spinophilin-mediated regulation of the α 2AAR in the pharmacology of the noradrenergic antidepressant DMI, and suggest that manipulation of this mode of receptor regulation may represent a novel and viable therapeutic strategy.
机译:人们广泛地理解许多抗抑郁药,包括三环抗抑郁药去甲丙啶(DMI),都可以通过调节中枢去甲肾上腺素能神经传递来发挥作用。 α2肾上腺素能受体(α2ARs)是去甲肾上腺素能系统的关键调节剂,先前的工作已经暗示α2ARs在啮齿动物强迫游泳试验(FST)中介导DMI的抗抑郁活性。但是,关于抗抑郁药物作用的细胞内调节剂知之甚少。 α2AR的功能受到其细胞内相互作用伴侣视紫红质和树突蛋白Spinophilin的严格调控。在经典的激动剂作用的背景下,我们先前已经确定了这些相互作用蛋白在α2AR上的竞争性和互补性,并已证明DMI是受体上直接抑制蛋白的配体。在本研究中,我们报告缺乏α2AAR亚型的小鼠在FST中缺乏DMI诱导的抗抑郁行为。同样,缺乏抑制蛋白3的小鼠缺乏对DMI的抗抑郁反应,而无纺锤蛋白的小鼠与野生型对照组相比,对DMI的抗抑郁反应增强,表明这种α2AAR介导的反应受抑制蛋白和纺粘蛋白的调节。经典的α2AR激动剂可乐定的抗抑郁作用具有α2AAR依赖性和restingin3参与的特征,但非三环去甲肾上腺素再摄取抑制剂瑞波西汀则无此作用,这支持了DMI通过直接参与α2AAR发挥其抗抑郁作用的模型和逮捕3。我们的研究结果表明,去甲肾上腺素能抗抑郁药DMI的药理作用涉及抑制蛋白和亲脂蛋白介导的α2AAR调节,并且表明对该受体调节模式的操纵可能代表了一种新颖且可行的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号